Search
Aclaris Therapeutics Inc
ACRSAdd to Watchlist
5.560USD
+0.220+4.12%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
776.53MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Aclaris Therapeutics Inc is 8.91, ranking 36 out of 387 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 16.00 and a low of 2.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
9.150
Target Price
+82.27%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Aclaris Therapeutics Inc
ACRS
12
Beigene Ltd
ONC
27
Ionis Pharmaceuticals Inc
IONS
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Aclaris Therapeutics Inc's expected revenue for the next quarter?
Aclaris Therapeutics Inc's expected revenue is 1.38M.
What is Aclaris Therapeutics Inc's price target?
Analysts forecast that Aclaris Therapeutics Inc's price target is USD 7.00, with the highest forecast at USD 16.00 and the lowest forecast at USD 2.00.
How have Aclaris Therapeutics IncACRS's recent earnings per share performed?
The market expectation was USD -0.15, while Aclaris Therapeutics IncACRS's earnings per share (EPS) for the previous quarter was USD -0.16. EPS for the next quarter is expected at USD -0.16.
What is the analyst rating for Aclaris Therapeutics Inc?
Based on the ratings of Aclaris Therapeutics Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.